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131I-Metaiodobenzylguanidine (131I-MIBG) has been used as a single agent or in combination with chemo-
therapy for the treatment of high-risk neuroblastoma. The activity and toxicity of 131I-MIBG when combined
with carboplatin, etoposide, and melphalan (CEM) and autologous stem cell transplantation (SCT) are now
investigated in a phase II multicenter study. Fifty patients with MIBG-avid disease were enrolled into 2 co-
horts, stratiﬁed by response to induction therapy. The primary study endpoint was response of patients with
refractory (n ¼ 27) or progressive disease (n ¼ 15). A second cohort of patients (n ¼ 8) with a partial response
(PR) to induction therapy was included to obtain preliminary response data. 131I-MIBG was administered on
day -21 to all patients, with CEM given days -7 to -4, and SCT given on day 0. 131I-MIBG dosing was deter-
mined by pre-therapy glomerular ﬁltration rate (GFR), with 8 mCi/kg given if GFR was 60 to 99 mL/minute/
1.73 m2 (n ¼ 13) and 12 mCi/kg if GFR  100 mL/minute/1.73 m2 (n ¼ 37). External beam radiotherapy was
delivered to the primary and metastatic sites, beginning approximately 6 weeks after SCT. Responses
(complete response þ PR) were seen in 4 of 41 (10%) evaluable patients with primary refractory or pro-
gressive disease. At 3 years after SCT, the event-free survival (EFS) was 20%  7%, with overall survival (OS)
62%  8% for this cohort of patients. Responses were noted in 3 of 8 (38%) of patients with a PR to induction,
with 3-year EFS 38%  17% and OS 75%  15%. No statistically signiﬁcant difference was found comparing EFS
or OS based upon pre-therapy GFR or disease cohort. Six of 50 patients had nonhematologic dose-limiting
toxicity (DLT); 1 of 13 in the low GFR and 5 of 37 in the normal GFR cohorts. Hepatic sinusoidal obstruc-
tive syndrome (SOS) was seen in 6 patients (12%), with 5 events deﬁned as dose-limiting SOS. The mediandgments on page 680.
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G.A. Yanik et al. / Biol Blood Marrow Transplant 21 (2015) 673e681674times to neutrophil and platelet engraftment were 10 and 15 days, respectively. Patients received a median
163 cGy (61 to 846 cGy) with 131I-MIBG administration, with 2 of 3 patients receiving >500 cGy experiencing
DLT. The addition of 131I-MIBG to a myeloablative CEM regimen is tolerable and active therapy for patients
with high-risk neuroblastoma.
 2015 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
Therapy for high-risk neuroblastoma commonly uses a
multimodal approach, combining induction chemotherapy
with surgical resection of soft tissue disease, autologous
hematopoietic stem cell transplantation (SCT), radiotherapy,
isotretinoin, and chimeric anti-GD2 antibody. However,
durable remission rates remain low, with 5-year event-free
survival (EFS) rates of 30% to 49% [1-3].
Radiolabeled metaiodobenzylguanidine (MIBG) was
developed in the early 1980s as a scintigraphic imaging agent
for both pheochromocytoma and neuroblastoma [4-6].
Historically, MIBG has been radiolabeled with either iodine-
131 or iodine-123, with 123I-MIBG used for imaging and
131I-MIBG used for therapeutic purposes. The agent is
transported through norepinephrine transporter channels to
the cytoplasm and mitochondria of tumors, potentially
delivering a lethal radiation dose to involved cells [7-10]. Its
utility in neuroblastoma imaging and therapy is well
recognized, with 90% of neuroblastoma expressing MIBG
avidity. The agent concentrates within all potential sites of
disease, including soft tissue, bone, and red marrow [11]. In
addition, MIBG concentrates in tumors with or without
MYCN ampliﬁcation and with favorable or unfavorable his-
tology, with uptake independent of tumor ploidy and cyto-
genetics [11].
131I-MIBG monotherapy trials began in the 1980s, with
phase I and II trials reporting response rates of 10% to 60% in
patients with chemo-refractory disease [12-22]. The primary
toxicity of 131I-MIBG therapy is hematologic, with stem cell
rescue typically required with doses  15 mCi/kg [20].
Nonhematologic toxicity has been mild with 131I-MIBG
monotherapy, with infusion-related emesis, hypothyroidism,
and infection reported at 10% to 20% [20]. In fact, a maximum
tolerated dose has yet to be reached in monotherapy trials,
with dosing limited by hematologic effects and environ-
mental exposure issues.
The ability to combine 131I-MIBG with adjuvant chemo-
therapy has been examined with a wide variety of agents,
including alkylators, topoisomerase inhibitors, and anthra-
cyclines [23,24]. In addition, 131I-MIBG has been incorporated
intomyeloablative transplantation regimens, with promising
response and safety proﬁles reported [22]. A phase I trial
through the New Approaches to Neuroblastoma Therapy
(NANT) consortium identiﬁed the maximum tolerated tose
for 131I-MIBG at 12 mCi/kg when combined with myeloa-
blative doses of carboplatin, etoposide, andmelphalan (CEM)
[21]. We are now reporting a phase II NANT trial of 131I-MIBG
plus CEM in patients with refractory or progressive disease
(PD) to determine the response rate and toxicity of this
combination regimen in a multicenter setting. A second
cohort of patients with a partial response (PR) to induction
were also examined, as such patients had an anticipated
5-year EFS < 30% at the time of study initiation in 2004 [25].
MATERIAL AND METHODS
Patient Population
Eligible patients were 1 to 30 years of agewith high-risk neuroblastoma.
Patients were stratiﬁed into 2 patient cohorts, based upon response toinduction therapy at study entry. The primary patient cohort (cohort 1)
consisted of patients with either no response (NR) to induction (primary
refractory) or PD at any point after diagnosis, based upon International
Neuroblastoma Response Criteria (INRC) [26]. A secondary cohort (cohort 2)
consisted of a small subset of patients with a PR at the end of induction,
which must have included at least 4 cycles of induction therapy. This group
remained in PR at the time of study entry, even if they had received further
interval therapy. Patients were excluded from cohort 2 if they had been
previously enrolled on a phase III Children’s Oncology Group (COG) neuro-
blastoma protocol.
All patients were required to haveMIBG-avid disease documentedwithin
6 weeks of enrollment, computed tomography (CT)/magnetic resonance
imaging (MRI) tumor imaging, and bilateral bone marrow (BM) aspirates/
biopsies within 4 weeks of enrollment. No prior myeloablative therapy, 131I-
MIBG therapy, total body irradiation, or whole abdominal external beam
radiotherapy (XRT) was allowed. No XRT was allowed within 6 weeks
(6months for total lung or craniospinal XRT) of enrollment. Prior hepatic XRT
was limited to <1800 cGy to more than 30% of the liver and/or 900 cGy to
more than 50% of the liver. Prior kidney XRTwas limited to less than 1200 cGy
to more than 33% of both kidneys. Adequate organ function, including a
glomerular ﬁltration rate (GFR) 60mL/minute/1.73m2was required. Before
the start of therapy, patients were grouped according to baseline GFR: normal
GFR (100 mL/minute/1.73 m2) or reduced GFR (60 to 99 mL/minute/
1.73 m2). Written informed assent/consent was obtained from all patients
(and/or legal guardians) before enrollment. The protocol was approved by the
radiopharmaceutical division of the United States Food and Drug Adminis-
tration. Patients received 131I-MIBG infusions at 1 of 4 designated NANTMIBG
centers, but they could receive CEM chemotherapy and stem cell infusion at
any NANT site. The trial was registered on ClinTrials.com as NCT00253435.
Hematopoietic Stem Cells
A minimum of 1.0  106 CD34þ cells/kg peripheral blood stem cells
(PBSC) or 1.5  108 mononuclear cells/kg purged BM were initially required
to be available before enrollment. The study was amended to mandate a
minimum of 2.0  106 CD34þ cells/kg PBSC after the ﬁrst 7 patients were
enrolled. Purged PBSC or BM were allowed, with purging performed
according to Food and Drug Administration IDE# BB-IDE 2259 [3]. A back-up
of  2.0  106 CD34þ cells/kg PBSC was recommended. CD34þ selected
products were not allowed. Stem cells were required to have no detectable
tumor by immunocytology or a negative BM by morphology within 4 weeks
of stem cell collection [27].
131I-MIBG Preparation and Treatment
The 131I-MIBG was synthesized and exchange labeled in the Phoenix
Laboratory at the University of MichiganMedical Center (patients 1 to 19) or
Draximage Canada (patients 20 to 50). Radiopurity was determined at the
synthesis site before shipment. Free radioiodide content was rechecked at
the treatment center before infusion. Patients were admitted to a lead-
shielded room at an MIBG center on day -21, with 131I-MIBG dosing (8 or
12 mCi/kg) based upon a patient’s baseline GFR (Table 1A, B). For thyroid
blockade, potassium iodide and potassium perchlorate were started 8 to
12 hours before 131I-MIBG infusion and continued for 42 days (potassium
iodide) and 5 days (potassium perchlorate), respectively. Foley catheters
were required for bladder protection for a minimum of 72 hours or until
discharge from radio-protective isolation. The 131I-MIBG dose was diluted in
30 to 50 mL of .9% normal saline and infused intravenously via central or
peripheral catheter over 2 hours. Patients subsequently remained in radio-
protective isolation until radiation emissions met institutional standards,
typically 3 to 7 days after 131I-MIBG infusion. Whole body emissions were
measured via hand-held or ceiling-mounted scintillation monitors at
speciﬁed intervals while in radio-protective isolation. Whole body absorp-
tion was subsequently calculated in real time, upon release from radio-
protective isolation and before initiation of CEM chemotherapy on day -7
before transplantation.
Myeloablative Conditioning Regimen
Carboplatin and etoposide were administered as a 96 hour infusion on
days -7 to -4, with melphalan administered as a rapid intravenous bolus on
Table 2
Overall Response Criteria
OR MIBG lesions* CT/MRI lesionsy BMz,x Catecholamines
CR CR CR CR Normal
VGPR CR VGPR CR Normal
Table 1A
Therapy Schema
Time Therapy
Day -21 131I-MIBG
Day -7 Carboplatin, etoposide, melphalan
Day -6 Carboplatin, etoposide, melphalan
Day -5 Carboplatin, etoposide, melphalan
Day -4 Carboplatin, etoposide
Day -3 Rest
Day -2 Rest
Day -1 Rest
Day 0 Stem cell infusion
Day þ42 Local XRT
Day þ60 Response evaluation*
XRT indicates external beam radiotherapy.
* Response evaluation performed approximately day þ60 after SCT,
provided the patient was at least 10 days after completion of XRT.
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adjusted based upon pre-therapy GFR [28]. After enrollment of the 28th pa-
tient, the protocol was amended to modify chemotherapy dosing based upon
131I-MIBG whole body emissions, with a 20% dose reduction with emissions
300 to 599 cGy and elimination of CEM altogether with emissions  600 cGy.
After enrollment of the 41st patient, the protocol was further amended to
eliminate CEM with emissions  500 cGy. Stem cells were infused 72 hours
after chemotherapy, on day 0. Granulocyte colonyestimulating factor (Neup-
ogen, Amgen, ThousandOaks, CA)was begunonday 0 and continued until the
absolute neutrophil count (ANC) was  1500/uL  3 consecutive days.
Post-transplantation Therapy
XRT to primary and metastatic sites (2160 cGy in 180 cGy/day fractions)
was administered no sooner than 42 days after transplantation, provided
the ANC was > 1000/uL and platelets > 30,000/uL. Patients with complete
response (CR) or PR to study therapy were recommended, but not
mandated, to receive 6 courses of isotretinoin, whereas patients with stable
disease (SD) or PDwere recommended to receive nonprotocol therapy at the
treating physician’s discretion. Supportive care, including antimicrobial
prophylaxis and transfusional support, were administered per institutional
guidelines, with pneumocystis prophylaxis recommended through
day þ180 after transplantation.
Response Evaluation
Primary response assessment was performed after completion of XRTon
day þ60 after SCT, provided patients were at least 10 days after completion
of the XRT. Overall response was graded by central review utilizing the
NANT Response Criteria, which utilize 3 components of response (MIBG, CT/
MRI, and BM). 123I-MIBG was required for MIBG scintigraphy. MIBG-avid
bone sites were graded in 9 anatomic sectors, with a tenth sector for
MIBG avid soft tissue sites, to obtain an overall Curie score [29,30]. The post-
therapy Curie score was divided by the Curie score at study entry to provide
a “relative score,” with a relative score of 0 deﬁned as CR, a score of .1 to .5
deﬁned as PR, a score of .6 to 1.0 deﬁned as SD, and any new lesions deﬁned
as PD. The CT/MRI response was graded using the Response Evaluation
Criteria in Solid Tumors (RECIST 1.0) for measurable soft tissue disease with
the sum of longest diameters (sLD) measured at study entry [31]. A CR was
deﬁned as disappearance of all target and nontarget lesions. Very good
partial response (VGPR) was deﬁned as > 90% decrease in sLD, PR deﬁned as
at least 30% decrease in sLD, SD deﬁned as change that did not meet deﬁ-
nition of PR or PD, and PD deﬁned as at least 20% increase in sLD or a new siteTable 1B
Study Dosing*
GFR Cohort
(mL/minute/1.73 m2)
131I-MIBG
(mCi/kg)
Carboplatin
(mg/m2)
Etoposide
(mg/m2)
Melphalan
(mg/m2)
For patients  12 kg
 100 12 1500 1200 180
60-99 8 Calvert
formulay
640 180
For patients  12 kg
 100 12 50 40 6
60-99 8 Calvert
formulay
21.2 6
* Indicates total dose administered.
y For the reduced GFR cohort (60 to 99 mL/minute/1.73 m2), the Calvert
formula (AUC 3.3 mg/mL*minute/day) was used.of tumor. Soft tissue lesions that remained stable in size after protocol
therapy were considered SD, even if MIBG uptake was no longer present
within those lesions. BM response was graded using standard morphology
[31]. A BM CR was deﬁned as no tumor cells on 2 bilateral BM aspirates and
biopsies obtained at least 3 weeks apart. For patients with BMmetastases at
enrollment, PD was deﬁned as a minimum of 25% tumor by marrow
morphology and a doubling in the amount of baseline marrow disease. Thus,
patients with 30% baseline marrow involvement would be considered PD if
the marrow disease progressed to 60% by the post-therapy assessment.
Patients with 5% marrow involvement at baseline would only be considered
PD if the marrow involvement increased to  25%. For patients without BM
involvement at study entry, PD was deﬁned as tumor seen on 2 consecutive
BM examinations done at least 3 weeks apart. SDwas deﬁned as any amount
of residual BM involvement not qualifying as CR or PD.
Overall response grading is shown in Table 2. An overall response of CR
was deﬁned as having CR or not involved for all 3 individual components
(MIBG, CT/MRI, bone marrow), coupled with the presence of normal urine
catecholamines. Overall response of VGPR was deﬁned as VGPR for CT/MRI
response, CR for MIBG-avid bone lesions, CR or not involved for bone
marrow response, with residual soft tissue lesions allowed to have persis-
tent MIBG uptake. Overall response of PR was deﬁned as PR for CT/MRI
response, MIBG response of CR or PR for bone lesions, MIBG response of SD,
PR, or CR for soft tissue lesions, or BM response of CR or not involved. Overall
response of SD was deﬁned as SD for 1 component, with SD or not involved
for other 2 components. Overall response of mixed response was deﬁned as
a CR or PR for 1 component, with SD for a second component, and CR, PR, SD,
or not involved for the third component. Overall response of PD was deﬁned
as PD for any 1 component or clinical progression based on physical exam by
treating physician.
MIBG scans on all patients had central review by a nuclear radiologist.
Central review of CT/MRI scans and BM biopsy slides were done for all
patients with an overall response of CR or PR. Patients with an overall
response of mixed response or SD had CT/MRI and BM central review if
these sites were reported to be involved at study entry. All radiology and
BM reports were reviewed centrally for all patients. The centrally reviewed
overall response for 12 patients was graded with a consensus committee,
the remainder were graded by 2 oncologists (authors J.G.V., K.K.M., G.Y.,
and/or A.M.).
Dose-Limiting Toxicities
Toxicity was graded according to Common Terminology Criteria version
3.0 criteria for all patients, stratiﬁed by GFR cohort (normal versus reduced
GFR). Hematologic dose-limiting toxicity (DLT) included primary graft fail-
ure, deﬁned as an ANC< 500/uL by day 28 after SCTor platelets< 20,000/uL
by day 56 after SCT, or a requirement for infusion of additional stem cells for
any medical reason before initial neutrophil or platelet engraftment. Sec-
ondary graft failure (not considered a DLT) was deﬁned as hematologic
failure after initial engraftment. Nonhematologic DLT included any grade 4
toxicities, excluding grade 4 fever, anorexia, inner ear (hearing), vomiting,
skin/mucositis in a previously radiated ﬁeld, or metabolic abnormalities
(unless deemed life threatening by the treating physician). Grade 4 in-
fections were not considered DLT unless associated with grade 3 organ
symptoms that did not resolve within 7 days of onset. As CommonPR CR, PR PR CR Any
MR CR, PR PR, SD SD Any
MR CR, PR SD CR, SD Any
MRjj SD CR, PR, SD CR, SD Any
SD SD SD SD Any
PD PD Any Any Any
PD Any PD Any Any
PD Any Any PD Any
OR indicates overall response; MR, mixed response.
For each patient, overall response was graded as a composite of their indi-
vidual CT/MRI, MIBG, bone marrow and catecholamine responses.
* For MIBG-avid skeletal disease (See Materials and Methods for MIBG-
avid soft tissue disease).
y CT/MRI applicable if soft tissue disease is present.
z Applicable if bone marrow involvement is present.
x Bone marrow is graded CR, SD, or PD. There is no PR grade.
jj CR/PR for CT/MRI, or CR for marrow is required.
Table 3
Patient Characteristics
Cohort 1
n (%)
Cohort 2
n (%)
All Patients
n (%)
Total patients 42 (84) 8 (16) 50 (100)
Age, median (range), yr 6.0 (1.2-22.8) 7.7 (4.2-16.3) 6.0 (1.1-22.8)
Gender
Female 10 (24) 2 (25) 12 (24)
Male 32 (76) 6 (75) 38 (76)
Time from diagnosis,
median (range), mo*
9.1 (5.3-102.2) 7.6 (4.1-17.4) 8.8 (4.1-102)
Sites of evaluable tumor
Skeletal 38 (90) 7 (88) 45 (90)
Marrow 25 (60) 2 (25) 27 (54)
Soft tissue 18 (43) 3 (38) 21 (42)
MYCN status
Ampliﬁed 1 (2) 2 (25) 3 (6)
Nonampliﬁed 28 (67) 2 (25) 30 (60)
Unknown 13 (31) 4 (50) 17 (34)
No. of prior regimens,
median (range)
2 (1-8) 1 (1-2) 2 (1-8)
Prior radiation therapy
Yes 4 (10) 0 (0) 4 (8)
No 38 (90) 8 (100) 46 (92)
Pretherapy status
Primary refractory 27 (64) NA 27 (54)
PDy 15 (36) NA 15 (30)
PR NA 8 (100) 8 (16)
Pretherapy GFRz
Normal GFR 30 (71) 7 (88) 37 (74)
Reduced GFR 12 (29) 1 (12) 13 (26)
PSC
Purged PSC 6 (14) 2 (25) 8 (16)
Unpurged PSC 36 (86) 6 (75) 42 (84)
Stem cell dose
Cell dose, median
(range)x
4.9 (1.1-29.5) 5.2 (2.2-8.7) 5.2 (1.1-29.5)
Post-therapy maintenancejj
Retinoids, no
Anti-GD2 therapy{
14 (33) 5 (63) 19 (38)
Retinoids þ anti-GD2
therapy#
5 (12) 3 (38) 8 (16)
Anti-GD2 therapy,
no retinoids
3 (7) 0 (0) 3 (6)
Other therapy only** 4 (10) 0 (0) 4 (8)
None 9 (21) 0 (0) 9 (18)
Unknownyy 7 (17) 0 (0) 7 (14)
PSC indicates peripheral stem cells.
* Time from initial diagnosis to study entry.
y Indicates disease progression at any point before study entry.
z Normal GFR  100 mL/minute/1.73 m2; reduced GFR, 60 to 99 mL/
minute/1.73 m2.
x Indicates median cell dose (  106 CD34/kg) for primary infusion.
jj Indicates therapy given after completing protocol therapy, and before
development of PD.
{ Retinoids (isotretinoin  fenretinide) alone, without immunotherapy.
# Anti-GD2 therapy includes ch14.18, 3F8, ch14.18-IL-2 fusion protein,
hu14.18.
** Other therapy includes therapies other than retinoids  anti-GD2
therapy.
yy Includes unknown receipt of anti-GD2 therapy (n ¼ 6) and unknown
receipt of retinoids (n ¼ 1).
G.A. Yanik et al. / Biol Blood Marrow Transplant 21 (2015) 673e681676Terminology Criteria version 3.0 did not include criteria for hepatic
sinusoidal obstructive syndrome (SOS), dose-limiting (severe) SOS was
deﬁned as hepatomegaly, right upper quadrant tenderness, and total
bilirubin > 2.0 mg/dL (>grade 1), plus grade 3 toxicities of either total
bilirubin, hypoalbuminemia, weight gain, or hypoxia. Nonedose-limiting
SOS was deﬁned as the presence of hepatomegaly, right upper quadrant
tenderness, and total bilirubin > 2.0 without any of the grade 3 abnormal-
ities listed above.
Statistical Design
This was a single-arm phase II trial with the primary endpoint of overall
response to the combination regimen. The statistical design, including
primary endpoint analysis and sample size calculations, were based upon
estimates for cohort 1. The primary study endpoint was overall response in
cohort 1, with overall responses of CR or PR considered responders. The
primary response assessment was performed day þ60 after SCT, provided
patients were  10 days after completion of XRT. If completion of XRT was
delayed for any medical reason beyond day þ60 after SCT, the primary
response assessment was still performed at least 10 days after completion of
the XRT. The study utilized a Bayesian design, assuming a Beta (7.5, 34.5)
prior distribution for the true probability of response, and would accrue a
minimum of 15 and a maximum of 40 subjects in cohort 1, with 3 interim
analyses based on the treating site’s response grading to determine if there
was a .90 posterior probability of at least a 10% response rate. The study
would stop for futility if  1 of 15,  2 of 25, or  3 of 35 patients ex-
perienced a response. Patients were evaluable for response if they
completed the primary response assessment, experienced toxicity requiring
early treatment termination (in which case they were considered non-
responders), or had PD before the primary response assessment. Accrual to
cohort 2 was continued until cohort 1 accrual was completed, with 1 interim
analysis to conﬁrm at least 1 responder among the ﬁrst 10 cohort 2 patients.
Patients were removed from protocol therapy for PD, DLT, initiation of
nonprotocol therapy, or protocol therapy completion, but they continued to
be followed for disease progression and survival. Fisher’s exact test was used
for testing the association of response with other factors.
Secondary endpoints included EFS, overall survival (OS), and toxicity.
The date of stem cell infusion was used as the starting point for Kaplan-
Meier estimates of EFS and OS [32] as well as for evaluating engraftment.
For EFS, an event was deﬁned as PD, death from any cause, or any secondary
malignancy. Details of nonprotocol therapy after transplantation (other than
start date) were obtained for isotretinoin, fenretinide, and anti-GD2 thera-
pies (Table 2). All patients were followed for last alive date until death, loss
to follow-up, or withdrawal of consent. For simple summary of outcome by
groups, the 3-year EFS and OS rates (ie, the chance at 3 years) were based on
Kaplan-Meier estimates; corresponding standard errors were based on
Greenwood’s formula. The log-rank test was used when comparing EFS, OS,
or time to engraftment between different groups. All reported P values are
2-sided.
RESULTS
Fifty patients were enrolled between March 2005 and
November 2009: 42 in cohort 1 and 8 in cohort 2 (Table 3).
All patients had MIBG-avid disease at baseline. For the entire
study population, the median age was 6.0 years (range, 1.1 to
22.8 years), with patients treated a median of 8.7 months
from initial diagnosis and receiving a median of 2 (range, 1 to
8) lines of chemotherapy. Patients in cohort 1 exhibited
either primary refractory (n ¼ 27) or PD (n ¼ 15) at study
entry, whereas all patients in cohort 2 (n ¼ 8) exhibited a
PR. Thirteen of the 50 patients had a reduced GFR (60 to
99 mL/minute/1.72 m2) at study entry; 12 of 42 (29%) in
cohort 1 and 1 of 8 (13%) in cohort 2. Overall response was
evaluated a median of 70 days after SCT (range, 34 to
111 days). Post-study maintenance therapy consisted of
retinoids (including isotretinoin and/or fenretinide) in 27
patients (Table 3); 8 concurrently with anti-GD2 therapy, and
3 patients receiving anti-GD2 therapy alone.
Response and Survival: Cohort 1
Forty-one of 42 patients in cohort 1 were evaluable for
primary response assessment. One patient was nonevaluable
because of surgical resection of his only measurable soft
tissue tumor after transplantation but before his responseassessment. A second patient expired from toxicity before
post-therapy response assessment; this patient could not be
assigned an overall response after therapy but was con-
sidered evaluable and a nonresponder for the statistical
endpoint.
Responses (CR þ PR) were seen 4 of 41 evaluable patients
(10%) in cohort 1 (Table 4). Site-speciﬁc responses were
additionally graded for 3 categories: MIBG, CT/MRI, and BM.
Using Curie scoring, MIBG scan responses (CR/PR) were
noted in 13 (33%) evaluable patients, whereas 26 (65%) pa-
tients achieved SD and 1 (3%) PD by MIBG scan assessment.
Table 4
Patient Responses
Disease Status* No. CR PR MR SD PD OR (%)
Cohort 1 41 3 1 8 23 6 4 (10%)
Cohort 2 8 2 1 2 3 0 3 (38%)
* Indicates risk group at study entry. Forty-nine of 50 patients were
evaluable for response. Mixed response deﬁned as improvement in 1 site
(CR/PR) with SD in other sites.
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measurable soft tissue disease present at study entry, with
SD in 17 (81%) patients and PD in 2 (10%) patients. Among 27
patients with morphologic tumor in the BM at study entry, 2
patients were not evaluable for marrow response because a
repeat BMwas not done (n¼ 1) or was an inadequate sample
(n ¼ 1). BM response in the remaining 25 patients was CR
(n¼ 4; 16%), SD (n¼ 19; 76%), and PD (n¼ 2; 8%). In 1 patient
classiﬁed as SD for marrow response, the BM involvement
decreased from 40% to <1% with study therapy. The patient
was still classiﬁed as SD on the basis of residual marrow
disease at 1 site. Based upon NANT response criteria, an
additional 3 patients with no tumor seen within the BM at
study entry were graded as SD for BM response, due to
detection of intermittent low level tumor (<5%) on subse-
quent 2 to 3 bone marrow samples, reﬂecting intermittent
detection of minimal residual BM tumor. All 3 of these pa-
tients were classiﬁed as nonresponders for the primary study
endpoint.
Catechol levels normalized in all 3 patients within cohort
1 who were deemed as having an overall response of CR. In
addition, overall response rates were similar between the 2
131I-MIBG suppliers, for patients receiving the University of
Michigan and Draximage products respectively (P ¼ 1.00,
Fisher’s exact test).
For cohort 1, the 3-year EFS was 20%  7% and 3-year OS
62%  8%. There were no signiﬁcant outcome differences
between patients enrolled with primary refractory (n ¼ 27)
and PD (n ¼ 15), with 3-year EFS 10%  6% versus 39%  13%
(P ¼ .37, log-rank test), and 3-year OS 66%  9% versus
60%  13%, respectively (P ¼ .17, log-rank test).Response and Survival: Cohort 2
Responses (CR/PR) were seen in 3 of 8 (38%) patients in
cohort 2. MIBG-based scan responses were noted in 5 (63%)
patients, CT/MRI responses in 1 of 3 (33%) patients with
measurable soft tissue disease at study entry, and marrow
responses in 0 of 2 cases with marrow involvement at entry.
Catecholamine levels normalized in the 2 complete re-
sponders within this cohort. The 3-year EFS and 3-year OS for
cohort 2 were 38%  17% and 75%  15%, respectively.Survival Comparisons
There was no signiﬁcant difference in outcome between
the 2 disease cohorts, including 3-year EFS (P ¼ .37 [log-rank
test]), and 3-year OS (P ¼ .17 [log-rank test]) (Figure 1A, B).
No outcome differences by baseline GFR were likewise
noted, with 3-year EFS 25%  7% for patients with normal
GFR and 17%  11% for those with a reduced GFR at study
entry (P¼ .82, log-rank test). The 3-year OSwas 66% 8% and
58%  14% for the normal and reduced GFR groups, respec-
tively (P ¼ .90, log-rank test).Curie Score and Outcome
The median Curie score at study entry was 8 (range, 1 to
25) for the entire study population; 9 (range, 1 to 25) for
cohort 1 and 5 (range, 1 to 8) for cohort 2. Baseline Curie
scores were not associated with outcome differences; 3-year
EFS 26%  9% for patients with baseline Curie scores  8
versus 20%  9% for those with Curie scores > 8 at study
entry (P ¼ .10 log-rank test). Nine patients exhibited a
baseline Curie score  2 at study entry, with 3-year EFS
27% 16% versus 20% 7% for those with baseline scores> 2
(P ¼ .42 log-rank test).
Toxicity from MIBG Infusion
All 50 patients were evaluable for regimen-related
toxicity, including hematologic and nonhematologic toxic-
ities. Forty-eight of 50 patients required radio-protective
isolation for  7 days, with 2 patients requiring 8 and 9 days
to meet institutional standards for release. Overall, the
131I-MIBG infusions were well tolerated, with only 2 severe
adverse events reported during or immediately after (within
2 weeks) 131I-MIBG administration: a catheter-related
bacteremia (1 patient) and a transient viral upper respira-
tory infection (1 patient). No grade 2 to 4 organ-related
toxicities were reported while patients were in radio-
protective isolation after MIBG infusion. One of the 2 pa-
tientswho requiredprolonged radio-protection subsequently
developed hepatic SOS after transplantation, associated with
a whole body radiation exposure > 600 cGy from the
131I-MIBG therapy. Given the organ toxicity observed in this
patient, the protocol was amended to dose reduce the CEM
chemotherapy in selected situations (see Material and
Methods). Two (9%) of the 22 subsequent patients had
chemotherapy reductions based upon this amendment, with
1 of the 2 patients having the chemotherapy omitted alto-
gether. All patients received stem cell infusions as prescribed
(21 days after the MIBG infusion), including the patient in
whom chemotherapy was held altogether.
Hematologic Toxicity
The median time to neutrophil (ANC  500/uL) and
platelet (20,000/uL) engraftment after SCT was 10 days
(range, 8 to 36 days) and 15 days (range, 3 to 75 days) after
SCT, respectively. One patient died on dayþ13 after SCT from
SOS, having engrafted neutrophils but before platelet
engraftment. Three patients developed primary graft failure,
requiring infusion of back-up, cryopreserved stem cells to
establish engraftment. Two of these 3 patients had received
< 2.0 106 CD34 cells/kgwith their initial transplantation. In
contrast, only 1 of 45 patients receiving  2.0  106 CD34
cells/kg PBSC exhibited primary graft failure. No cases of
secondary graft failure were noted. Eight patients received
purged PBSC. There was no statistically signiﬁcant difference
in terms of time to engraftment of neutrophils (10 days
versus 10 days, P ¼ .51) or platelets (15 days versus 15 days,
P ¼ .84) in hematopoietic stem cell products that were
purged (n ¼ 8) or nonpurged (n ¼ 42). There were no sta-
tistically signiﬁcant differences in time to engraft between
cohort 1 and 2 (P¼ .51 for neutrophil engraftment and P¼ .26
for platelet engraftment, log-rank test). One patient was
diagnosedwith acutemyelogenous leukemia (AML) 3.6 years
after stem cell infusion.
Nonhematologic Toxicity
Grade 3 to 4 non-hematologic toxicities are summarized
in Table 5, with all toxicities occurring post-SCT. Overall,
Figure 1. (A) EFS, based upon disease status at study entry: cohort 1 (primary refractory/PD) and cohort 2 (PR to induction). (B) OS, based upon disease status at study
entry: cohort 1 (primary refractory/PD) and cohort 2 (PR to induction).
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no signiﬁcant difference in the incidence of hepatic SOS
between the normal and reduced-GFR cohorts, 14% versus
8%, respectively. Among the 6 patients who experienced
SOS, the median time to SOS onset was 8 days (range, 5 to
12 days) after SCT. In 4 cases, the hepatic SOS was associated
with grade 3 to 4 hypoxia. Two of the 6 cases of SOS were
fatal, at 13 and 71 days after stem cell infusion; 1 from
hepatic dysfunction and the second from combined hepatic
dysfunction/pulmonary ﬁbrosis in a patient who had pre-
viously received mediastinal XRT. Deﬁbrotide was admin-
istered in 1 of the 2 fatal cases. The SOS resolved in the
remaining 4 cases after supportive care management alone.Thirty-ﬁve (70%) patients developed grade 3 to 4 febrile
neutropenia. Bacteremia was reported in 14 patients, with
either gram positive (n ¼ 6) or gram negative organisms
(n ¼ 3). No invasive fungal infections, viremia, Pneumocystis
jirovecii, or infections due to other atypical organisms were
noted.
There was no signiﬁcance difference in the incidence or
severity of events based upon 131I-MIBG supplier. Five of 19
(26%) patients treated with 131I-MIBG supplied by the
University of Michigan Phoenix Laboratory developed a DLT
over the course of study, compared with 5 of 31 (16%)
treated with 131I-MIBG supplied by Draximage (P ¼ .47,
Fisher’s exact test).
Table 5
Incidence of Grade 3 to 4 Events based on CTCAE v3
Toxicity Normal GFR Reduced GFR All
No. patients 37 13 50
Stomatitis/Mucositis* 25 (68) 6 (46) 32 (64)
Infection
Febrile Neutropenia 24 (65) 11 (85) 35 (70)
Bacteremia 11 (30) 3 (23) 14 (28)
Sepsis 2 (5) 0 (0) 2 (4)
Hypoxiay 8 (22) 1 (8) 9 (18)
SOSz 5 (14) 1 (8) 6 (12)
Data presented are (n) %.
CTCAE v3 indicates Common Terminology Criteria for Adverse Events
version 3.
* Oral, esophageal, gastrointestinal.
y Requirement for supplemental oxygen support.
z Indicates overall incidence of SOS (dose limiting plus non-dose
limiting).
G.A. Yanik et al. / Biol Blood Marrow Transplant 21 (2015) 673e681 679Deaths
Overall, 28 patients died. Two from organ-related
toxicity/SOS related to protocol therapy, 2 from multiorgan
failure related to subsequent therapy received after ending
this protocol, and 23 from disease progression, including 1
patient who developed secondary AML 3þ years after
completion of study therapy. The patient ultimately died
from progressive neuroblastoma with the AML in remission.
No other study patients developed a secondary leukemia or
secondary malignancy.Whole Body Dosimetry
Whole body dosimetry was available in 47 of 50 patients.
The measurements were obtained while in radio-protective
isolation after the 131I-MIBG infusion. Patients received a
median of 163 cGy (range, 61 to 846 cGy) during the 131I-
MIBG portion of therapy. The 3-year EFS after SCT
was 19%  9% for the 24 patients with a whole body
absorption  163 cGy, with 3-year OS 64%  10%. By com-
parison, the 3-year EFS was 20%  9% and 3-year OS
64%  10% for 23 patients with whole body absorption levels
> 163 cGy (P ¼ .80 and P ¼ .72 for EFS and OS, respectively).
For the reduced-GFR cohort, the median whole body ab-
sorptionwas 110 cGy (range, 61 to 160 cGy) compared with a
median whole body absorption 172 cGy (range, 101 to
846 cGy) in the normal-GFR cohort, P < .001.
From a toxicity standpoint, there was no statistically sig-
niﬁcant difference in whole body absorption in patients
developing SOS (n ¼ 6) compared with the entire study
population (n ¼ 50), with a median exposure 174 cGy
(range,125 to 676) versus 162 cGy (range, 61 to 846) (P ¼ .32,
Wilcoxon test). For the 2 fatal cases of SOS, the whole body
absorption levels were 150 cGy and 676 cGy. Two of 3
patients receiving > 500 cGy experienced DLT, with 1 dose-
limiting SOS (noted above) and the other a grade 4 infection.DISCUSSION
This phase II study of 50 patients treated with a targeted
radiotherapy agent (131I-MIBG) plus myeloablative chemo-
therapy and autologous stem cell rescue conﬁrms the toler-
ability and activity of this regimen. Although the response
rate was low (10% in patients with primary refractory or PD,
the 3-year EFS (20%) and 3-year OS (62%) rates are encour-
aging for this highly refractory patient population, and they
compare favorably with a recent COG protocol for relapsed or
refractory disease [33].131I-MIBG has been historically administered either as a
single agent (monotherapy) or in combination with sub-
ablative or high-dose chemotherapy, primarily for patients
with refractory or PD [21,34-37]. A dose-dependent response
has been noted, with dose escalation from 3 to 21 mCi/kg
associated with increasing tumor response [17]. A multi-
center trial of 164 patients treated with 131I-MIBG mono-
therapy noted responses rates of 25% and 37% for patients
treated with 12 mCi/kg or 18 mCi/kg, respectively [20]. A
NANT phase I trial (NANT 9901), combining 131I-MIBG
(12 mCi/kg) with CEM chemotherapy and autologous stem
cell rescue for patients with primary refractory disease,
noted responses in 27% of patients, with a 3-year EFS of 28%
and 3-year OS of 56% [21]. Our current study was based upon
NANT 9901, with 13 patients receiving 8 mCi/kg and 37
receiving 12 mCi/kg of 131I-MIBG, with dosing stratiﬁed by
their pre-therapy GFR measurements. Whether response
rates could be higher with further dose escalation of the
131I-MIBG, or use of transplantation regimen other than CEM,
will be investigated in current and future clinical trials. Our
response rates in measurable soft tissue sites were also lower
than expected, given prior reports of 50% response rates in
soft tissue disease [20,36]. Interpretation of our 3-year EFS
and OS must be cautioned, as patients were allowed to
proceed to off-protocol therapy after completion of the
primary response endpoint (median day þ70 after SCT). In
the current trial, 22% of patients received anti-GD2 therapy
after completion of study therapy, with 54% receiving a
retinoid, (either isotretinoin, fenretinide, or both). Our phase
II study was not designed to examine EFS and OS as primary
endpoints, given the confounding variables that post-
protocol therapy would add. Another variable was the
paucity of patients with MYCN ampliﬁed disease in cohort 1
(Table 2). The impact of this factor on study outcome is not
known, as prior MIBG therapy studies either have not
investigated or reported outcome differences in patients
with MYCN ampliﬁed versus nonampliﬁed disease.
The optimal time to administer 131I-MIBG therapy re-
mains under investigation. 131I-MIBG therapy has historically
focused on the treatment of patients with relapsed or re-
fractory disease and was the primary focus of the current
trial. However, single-center or small pilot studies suggest
activity when given at the time of diagnosis or when given in
conjunction with induction chemotherapy [24,38]. In our
current study, MIBG scan responses were seen in 5 of 8
patients (63%) in cohort 2. Though the small sample size of
cohort 2 limits our conclusions, larger clinical trials exam-
ining the role of MIBG as front-line therapy are being
considered by COG. Finally, day -21 before transplantation
was selected for administration of the MIBG based upon
historical data, in which MIBG induced signiﬁcant marrow
suppression 14 to 21 days after administration [17,22]. In our
current trial, we timed the administration of the MIBG with
the high-dose chemotherapy in such a manner that the
marrow suppressive effects of each (MIBG and CEM
chemotherapy) occurred concurrently.
The majority of 131I-MIBG therapy trials to date have been
single center or limited institution studies, often retrospec-
tive in nature, with response assessments based upon 1993
INRC criteria or based upon review of MIBG scans alone.
MIBG-based responses were ill-deﬁned by such INRC criteria,
with qualitative assessments used to determine responses on
MIBG scans, in comparison with the semi-quantitative Curie
scoring used in this and other NANT trials [23,35]. In addi-
tion, because of the known sampling error with BM disease
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may downgrade overall response. For example, 1 patient in
our study was graded with an overall response of SD on the
basis of residual minimal (<1%) BM involvement, though the
patient had complete resolution of all CT/MRI andMIBG-avid
disease, and though they had presented with 40% marrow
involvement at study entry. In addition, patients who per-
sisted with any measurable soft tissue disease at study
completion were also deemed nonresponders, even if they
had complete resolution of MIBG uptake in that soft tissue
site.
The administration of 131I-MIBG on day -21 before trans-
plantation did not affect hematologic recovery after trans-
plantation, with a median time to neutrophil (ANC 500/uL)
and platelet (20,000/uL) recovery of 10 and 15 days,
respectively, similar to non-MIBG neuroblastoma trans-
plantation regimen [3,25]. Furthermore, hematologic toxicity
was not increased in patients with marrow involvement at
study entry, again suggesting the 131I-MIBG had little impact
on post-transplantation marrow recovery, even in these
heavily pretreated patients who had often received 2 ormore
regimens before transplantation. Though 3 cases of delayed
engraftmentwerenoted, 2 of the 3 caseswere associatedwith
infusion of suboptimal CD34 stem cell doses (<2.0  106
CD34/kg). In all 3 cases, rapid neutrophil and platelet en-
graftment occurred after administration of additional stem
cells. Engraftment rates were similar whether purged (8
cases) or unpurged products (42 cases) were used. We
recommend that all patients receiving 131I-MIBG therapy
in conjunction with myeloablative chemotherapy receive
> 2.0  106 CD34/kg stem cells.
Likewise, the addition of the 131I-MIBG to the CEM pre-
parative regimen did not result in increased nonhematologic
organ toxicity, when compared with historical trials with
CEM alone. In the current trial, the onset and duration of
adverse events were typical for a non-MIBG transplantation
regimen. A useful benchmark for comparison is the COG
study, COG A3973, in which myeloablative doses of CEM
(without MIBG) were administered to 372 patients under-
going autologous transplantation for high-risk neuroblas-
toma [3]. Similar rates of mucositis/stomatitis with no
signiﬁcant differences in hematologic or nonhematologic
toxicities existed between COG A3973 and our current phase
II trial (Table 6). In particular, the incidence of dose-limiting
(“severe”) SOS rates in our MIBG-CEM trial (10%) appear
comparable with SOS rates seen in COG A3973 (8%).Table 6
Comparison of COG A3973 to NANT 01-02
COG A3973 NANT 01-02 P Value
Transplantation regimen CEM MIBG-CEM
Total no. patients 372 50
Toxic death rate, n (%) 2 (3.2) 2 (4.0) .68
Dose-limiting SOS, n (%)* 29 (8) 5 (10) .58
Days to ANC > 500 (median)y 11/12 10 NA
Days to platelets > 20K (median)z 19/28 15 NA
Graft failure, n (%)
Primary 5 (1.3) 3 (6) .22
Secondary 6 (1.6) 0 (0)
NA indicates not applicable.
* For NANT 01-02: dose-limiting SOS occurred in 5 patients, with 6 cases
of SOS overall (1 non-DLT).
y For COG A3973: ANC recovery after nonpurged stem cell product/
purged product.
z For COG A3973: Platelet recovery after nonpurged stem cell product/
purged product.Post-induction Curie scores have previously shown
prognostic signiﬁcance in COG A3973, with Curie scores >2
associated with 3-year EFS 15.4%  5.3% [30]. In our current
study, 38 patients exhibited a Curie score >2 at study entry,
with 3-year EFS similarly low, 20%  7%. Direct comparisons
between the 2 trials are difﬁcult based upon Curie scores, as
patients were eligible for a MIBG-based transplantation in
our current study evenwith disease progression (n¼ 15), the
same cohort excluded from transplantation on the COG
A3973 study.
A major ﬁnding of our study was the need to perform
whole body dosimetry in “real time,” with chemotherapy
dose reductions required depending upon whole body
dosimetry measurements determined from the 131I-MIBG
portion of therapy. Grade 3 to 5 organ toxicities were noted
in 2 of 3 patients receiving > 500 cGy of whole body absor-
bed dose after the 131I-MIBG infusion, with a series of study
amendments implemented to decrease the chemotherapy
dosing in patients with elevated (>500 cGy) whole body
exposure. After implementation of these dosing changes, no
nonhematologic DLT (including SOS) occurred in any of the
remaining patients treated.
In summary, the combination of 8 to 12 mCi/kg of
131I-MIBG plus myeloablative doses of CEM chemotherapy
was associatedwithpromisingEFS andOS, though lowoverall
response rateswere seen inpatientswith relapsedor primary
refractory disease. Higher response rateswere seen in a small
cohort of patients treated after a PR to induction therapy,
suggesting that this combination should be studied further in
patients in ﬁrst response during induction. The addition of
131I-MIBG to the transplantation preparative regimen did not
result in increased hematologic or nonhematologic organ
toxicity, when compared to the published experience with
CEM alone. Engraftment was brisk, with low risk for graft
failure (<5%) when stem cell doses > 2.0  106 CD34 cells/kg
were administered. Clinical trials examining the role of
131I-MIBG in treating patients before the development of
primary refractory or PD, using doses 12mCi/kg, are now in
progress. In the future, a randomized trial comparing mye-
loablative therapywith or without 131I-MIBGwill be required
to determine the effectiveness of this regimen.ACKNOWLEDGMENTS
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